Investigating how a vaccine influences immune responses to protect against SIV infection
Official title: Project 2: Systems biology analyses of RHCMV/SIV and IL-15 mechanisms of immune programming
Funded at University of Washington · NIH-10897327 · Data updated 2026-11-12
This study is looking at how a special vaccine helps the immune system fight off SIV infection, and if you join by giving a blood sample, you can help researchers discover what makes the vaccine work better.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 1, 2023 |
| Project end | August 2, 2024 |
| Funding year | 2024 |
| Award (this year) | $19,176 |
| NIH project number | 5P01AI177688-02 |
| Project ID | NIH-10897327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals who are healthy and willing to provide blood samples for immune response analysis.
✕Less likely to help
Patients with existing SIV infections or those who are immunocompromised may not benefit from this research.
What this research studies
This research explores how the IL-15 and RhCMV/SIV vaccine programs the immune system to provide protection against SIV infection. By analyzing blood samples, the study aims to identify specific molecular responses that predict vaccine efficacy. The approach involves advanced techniques such as single-cell RNA sequencing and bioinformatics to understand the immune signatures associated with successful vaccination. Patients may contribute by providing blood samples, which will help researchers understand the immune mechanisms at play.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccine strategies that enhance protection against SIV and potentially other viral infections.
How similar studies have gone: Previous research has shown promise in using systems biology approaches to understand immune responses, indicating potential for success in this novel application.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Gale, Michael — University of Washington
- Study coordinator: Gale, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.